[On the pharmacology of N-(2-guanidinoethyl)-4-methyl-1,2,3,6-tetrahydropyridine, a new antihypertensive-acting compound].
D000311:Adrenal Glands / Q000032:analysis; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects*; D001923:Brain Chemistry; D002395:Catecholamines / Q000032:analysis*; D002415:Cats; D004336:Drug Antagonism; D004357:Drug Synergism; D006146:Guanidines / Q000494:pharmacology*; D006168:Guinea Pigs; D006973:Hypertension / Q000188:drug therapy; D051379:Mice; D009206:Myocardium / Q000032:analysis; D009541:Nictitating Membrane / Q000187:drug effects; D009638:Norepinephrine / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D013565:Sympatholytics / Q000494:pharmacology*; D014439:Tyramine / Q000494:pharmacology
D000959:Antihypertensive Agents; D002395:Catecholamines; D006146:Guanidines; D011725:Pyridines; D013565:Sympatholytics; D009638:Norepinephrine; D014439:Tyramine
Zur Pharmakologie von N-(2-Guanidinoäthyl)-4-methyl-1,2,3,6-tetrahydropyridin, einer neuen antihypertensiv wirkenden Verbindung.